Mostrar el registro sencillo del ítem

Artículo

dc.creatorRodríguez Pallares, Jannettees
dc.creatorRodrgíuez Pérez, Anaes
dc.creatorMuñoz, Anaes
dc.creatorParga, Juanes
dc.creatorToledo Aral, Juan Josées
dc.creatorLabandeira García, Josées
dc.date.accessioned2020-04-29T18:13:39Z
dc.date.available2020-04-29T18:13:39Z
dc.date.issued2016-04-13
dc.identifier.issn2157-6564es
dc.identifier.urihttps://hdl.handle.net/11441/95994
dc.description.abstractIn models of Parkinson’s disease (PD), Rho kinase (ROCK) inhibitors have antiapoptotic and axonstabilizing effects on damaged neurons, decrease the neuroinflammatory response, and protect against dopaminergic neuron death and axonal retraction. ROCK inhibitors have also shown protective effects against apoptosis induced by handling and dissociation of several types of stem cells. However, the effect of ROCK inhibitors on dopaminergic cell grafts has not been investigated. In the present study, treatment of dopaminergic cell suspension with ROCK inhibitors yielded significant decreases in the number of surviving dopaminergic neurons, in the density of graft-derived dopaminergic fibers, and in graft vascularization. Dopaminergic neuron death also markedly increased in primary mesencephalic cultures when the cell suspension was treated with ROCK inhibitors before plating, which suggests that decreased angiogenesis is not the only factor leading to cell death in grafts. Interestingly, treatment of the host 6-hydroxydopamine-lesioned rats with ROCK inhibitors induced a slight, nonsignificant increase in the number of surviving neurons, as well as marked increases in the density of graft-derived dopaminergic fibers and the size of the striatal reinnervated area. The study findings discourage treatment of cell suspensions before grafting. However, treatment of the host induces a marked increase in graft-derived striatal reinnervation. Because ROCK inhibitors have also exerted neuroprotective effects in several models of PD, treatment of the host with ROCK inhibitors, currently used against vascular diseases in clinical practice, before and after grafting may be a useful adjuvant to cell therapy in PDes
dc.description.sponsorshipMinisterio de Salud PI12/00798; RD12/0019/0020es
dc.description.sponsorshipMinisterio de Economía y Competitividad BFU2012-3708es
dc.formatapplication/pdfes
dc.format.extent12es
dc.language.isoenges
dc.publisherWiley Onlinees
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectParkinson’s diseasees
dc.subjectRho kinase (ROCK) inhibitorses
dc.subjectStem Cellses
dc.subjectCell Therapy in PDes
dc.titleEffects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease.es
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Fisiología Médica y Biofísica.es
dc.identifier.doi10.5966/sctm.2015-0182es
dc.contributor.groupUniversidad de Sevilla. CTS517: Fisiología molecular.es
dc.journaltitleStem Cells Translational Medicinees
dc.publication.volumen5es
dc.publication.issue6es
dc.publication.initialPage804es
dc.publication.endPage815es

FicherosTamañoFormatoVerDescripción
Effects of Rho Kinase Inhibitors ...2.319MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional